ARCTURUS THERAPEUTICS HLDGS's ticker is ARCT and the CUSIP is 03969T109. A total of 145 filers reported holding ARCTURUS THERAPEUTICS HLDGS in Q2 2023. The put-call ratio across all filers is 1.73 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $35,617 | -10.9% | 1,394 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $39,980 | +19.7% | 1,394 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $33,414 | +41.3% | 1,394 | 0.0% | 0.00% | +100.0% |
| Q4 2022 | $23,642 | +14.4% | 1,394 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $20,659 | -5.8% | 1,394 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $21,942 | -41.6% | 1,394 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $37,582 | -83.9% | 1,394 | -77.9% | 0.00% | -66.7% |
| Q4 2021 | $233,496 | -22.5% | 6,309 | 0.0% | 0.00% | -25.0% |
| Q3 2021 | $301,444 | +42.6% | 6,309 | +1.0% | 0.00% | +33.3% |
| Q2 2021 | $211,398 | -18.1% | 6,247 | 0.0% | 0.00% | -25.0% |
| Q1 2021 | $258,001 | -4.8% | 6,247 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $270,995 | +33.5% | 6,247 | +32.1% | 0.00% | 0.0% |
| Q3 2020 | $202,917 | +4.0% | 4,730 | +13.3% | 0.00% | +33.3% |
| Q2 2020 | $195,093 | – | 4,174 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DFPG INVESTMENTS, LLC | 183,803 | $9,359,000 | 5.00% |
| DAFNA Capital Management LLC | 229,652 | $9,852,000 | 3.20% |
| HealthCor Management, L.P. | 1,594,452 | $68,402,000 | 2.74% |
| Capital Impact Advisors, LLC | 110,000 | $4,719,000 | 1.40% |
| Cormorant Asset Management, LP | 700,000 | $30,030,000 | 1.16% |
| ARK Investment Management | 2,495,842 | $107,072,000 | 0.64% |
| Millrace Asset Group, Inc. | 18,087 | $776,000 | 0.63% |
| COOPER CREEK PARTNERS MANAGEMENT LLC | 50,532 | $2,168,000 | 0.54% |
| Endurant Capital Management LP | 34,485 | $1,479,000 | 0.44% |
| HealthCor Management, L.P. | 200,000 | $8,580,000 | 0.34% |